Kairos Pharma, Ltd.
https://kairospharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kairos Pharma, Ltd.
Finance Watch: BioAge Raises $198m In 20th Biopharma IPO Of 2024
Public Company Edition: BioAge will fund a Phase II trial of its muscle atrophy prevention drug in combination with an obesity drug with its initial public offering proceeds. Also, Ascendis and Wave raised $281.3m and $200m, respectively, after positive clinical trial readouts.
Finance Watch: Follow-Ons Bring In Big Post-Data Cash For Nuvalent And Others
Public Company Edition: Follow-on public offerings brought in $500m for Nuvalent, $235m for Summit and $225m each for Centessa and Viridian after recent readouts. Also, Kairos raised $6.2m in this year’s 19th IPO, Bayer sold €750m ($834m) in bonds and an Ionis FOPO grossed $500.3m.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice